Shares shifted sharply as NeOnc Technologies (NTHI), a tiny clinical-stage biotech developing experimental brain cancer treatments, saw its stock whipsaw following a June 10 agreement to sell up to $5 million in Series A Convertible Preferred Stock. The stock surged 14.9% to $5.18 on June 16 before retreating 7.3% to $4.80 in after-hours trading — a pattern that screams speculative enthusiasm colliding with dilution anxiety.
A Company Running on Fumes Needed the Cash Badly. At March 31, 2026, NeOnc had just $138,601 in cash.
Its own SEC filing flagged "substantial doubt" about its ability to continue operating.
A prior $10 million credit line was expected to fund operations only into September 2026. The new $5 million preferred deal, while modest, buys a few extra months of runway for a company that posted a $8.8 million net loss in Q1 alone. Without recurring revenue — full-year 2025 revenue was just $39,990 — every dollar comes from Wall Street, not patients.
The Preferred Stock Terms Cut Both Ways. The deal authorizes up to 6,000 shares at $833.34 each, convertible into common stock.
The financing includes a discounted conversion feature if not redeemed, but also contains a company redemption option, ownership caps, and a conversion floor price — meaning there's a limit to how cheaply new shares can flood the market. Preferred holders get no voting rights , preserving management control. Still, with only 26 million shares outstanding , any conversion adds meaningful dilution to existing holders.
Clinical Milestones Are the Real Story — and the Real Risk. NeOnc's lead brain-cancer treatment is in a fully enrolled mid-stage trial, with interim data expected around August 2026.
Its second drug candidate completed early-stage testing and locked in a recommended dose.
Three analyst firms have initiated coverage with favorable ratings , and CEO Heshmatpour has personally bought over $500,000 in shares. But insider conviction doesn't pay for trials.
The Bigger Picture: Serial Fundraising Is the Business Model. This $5 million raise follows a $13 million private placement earlier in 2026 and a $75 million at-the-market equity program launched in April. Each round keeps the lights on but chips away at per-share value. The stock trades at roughly half its 52-week high of $12.99, and until clinical data validates the science, NeOnc remains a company whose primary product is its own stock.